MedTrace Logo

Pharmacokinetics of Resveratrol Comprising Products

NCT01747252 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-05-03

No results posted yet for this study

Summary

This study was designed to assess the pharmacokinetics of 2 doses of Red Grape Cells (RGC) containing resveratrol compared with a reference. RGC will be administered as single oral dose to fasting healthy volunteers. Plasma concentration of free resveratrol and total conjugates will be analyzed.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

RGC

DIETARY_SUPPLEMENT

RGC

DIETARY_SUPPLEMENT

Resveratrol

The equivalent of 150 mg resveratrol

Sponsors & Collaborators

  • Fruitura Bioscience Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-10-31
Completion
2013-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747252 on ClinicalTrials.gov